Twist Bioscience Corporation Net Fee Amt
Twist Bioscience Corporation (TWST) had Net Fee Amt of $690.48 as of 2026-08-19, per its 424B7 filed 2026-08-19.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-19
- 2026-08-19: Net Fee Amt $690.48.
- 2026-08-05: Net Fee Amt $47.64K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-19 | $690.48 424B7 · filed 2026-08-19 |
| 2026-08-05 | $47.64K 424B5 · filed 2026-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |